- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 2 - Genetics and Next-Generation Sequencing
Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.
Dr Kumar continues his analysis of the genetic and familial probability of a patient being diagnosed with multiple myeloma.
Dr Chernew questions the value of circulating plasma cells as independent prognostic markers in newly diagnosed multiple myeloma, as well as circulating serum microRNAs for diagnosis of multiple myeloma.
The panelists then discuss next-generation sequencing, deep sequencing, and ASO-qPCR in detecting minimal residual disease (MRD). Dr Kumar says there is a growing interest in MRD and explains all the emerging developments for detection of MRD.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
